RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

Rhea-AI Summary

RxSight (Nasdaq: RXST), a medical device company specializing in customized vision solutions for cataract surgery patients, has appointed Raymond W. Cohen to its Board of Directors. Cohen, a seasoned medical technology executive with over 40 years of experience, notably led Axonics Inc. to generate over $1 billion in revenue within four years before its $3.7 billion acquisition by Boston Scientific in 2024.

As chairman of SoniVie Ltd., Cohen recently orchestrated its $600 million sale to Boston Scientific in March 2025. He currently serves on multiple healthcare company boards and brings extensive experience in scaling medical technology companies. Cohen expressed confidence in helping RxSight strengthen its position in the premium intraocular lens market and accelerate revenue and profit growth.

Positive

• Appointment of highly experienced medical technology executive with 40+ years of industry experience
• New director has proven track record of generating significant revenue ($1B+ at Axonics in 4 years)
• Cohen's expertise in successful M&A deals (led $3.7B Axonics sale and $600M SoniVie sale)
• Strategic addition to support company's growth and market expansion plans

Negative

• Indication of needed growth recovery ('get back on its growth track')
• Current challenges in premium intraocular lens market position

ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors.

“We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors,” said J. Andy Corley, Chairman of the Board at RxSight. “Ray’s extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system, enabling more physicians and patients to benefit from truly customized vision after cataract surgery.”

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of industry experience. He was the co-founder and chief executive officer of Axonics, Inc. (Nasdaq: AXNX) a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America and was acquired by Boston Scientific in 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical stage company, led the sale of that company to Boston Scientific for $600 million.

“I see tremendous potential for RxSight to get back on its growth track by strengthening its position in the premium intraocular lens market,” said Raymond W. Cohen. “Over the years, RxSight has demonstrated exceptional outcomes for cataract surgery patients with its groundbreaking RxSight Light Adjustable Lens system. I look forward to collaborating with the Board and management team to support the company’s mission to accelerate growth in revenue and profits.”

Cohen currently serves on the boards of several innovative healthcare companies, including Kestra Medical Technologies (Nasdaq: KMTS), where he is an independent director and chair of the compensation committee; InspireMD (Nasdaq: NSPR) as an independent director, as well as privately-held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Andera Partners and Sherpa Capital Partners.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated contributions of Raymond W. Cohen as a member of RxSight’s Board of Directors, RxSight’s ability to advance its strategy, return to a growth trajectory, and accelerate revenue and profit expansion, as well as RxSight’s ability to expand the reach of the RxSight® Light Adjustable Lens system and enable customized vision outcomes for more patients. These statements are based on current expectations and assumptions and involve known and unknown risks and uncertainties, many of which are beyond the company’s control.

Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those expressed or implied in these statements. Words such as “may,” “will,” “expect,” “anticipate,” “intend,” “believe,” “plan,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements. Any forward-looking information contained in this press release speaks only as of the date hereof, and RxSight undertakes no obligation to update or revise such statements to reflect new information, future events, or otherwise, except as required by law.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

FAQ

Who is Raymond W. Cohen, the new board member of RxSight (RXST)?

Raymond W. Cohen is a veteran medical technology executive with over 40 years of experience, former CEO of Axonics Inc., where he led the company to $1 billion in revenue and a $3.7 billion acquisition by Boston Scientific in 2024.

What experience does Raymond Cohen bring to RxSight's board?

Cohen brings 40+ years of medical technology experience, successful leadership of Axonics to $1B+ revenue, expertise in M&A deals, and currently serves on multiple healthcare company boards including Kestra Medical Technologies and InspireMD.

What is RxSight's (RXST) main business focus?

RxSight is an ophthalmic medical device company that provides high-quality customized vision solutions to patients following cataract surgery through their RxSight Light Adjustable Lens system.

What are Raymond Cohen's current board positions as of 2025?

Cohen serves as an independent director at Kestra Medical Technologies and InspireMD, chairman of Nalu Medical and Archimedes Vascular, vice chairman of Tulavi Medical, and director at Spectrum Vascular.

What major deals has Raymond Cohen led recently before joining RxSight?

Cohen led the $3.7 billion sale of Axonics to Boston Scientific in 2024 and the $600 million sale of SoniVie to Boston Scientific in March 2025.